DUBLIN, Ohio, June 12, 2006— Cardinal Health, Inc., the leading provider of products and services supporting the health-care industry, issued the following statement concerning release of the Food and Drug Administration’s (FDA) anti-counterfeit report and recommendation to implement provisions of the Prescription Drug Marketing Act (PDMA).
Cardinal Health applauds steps taken by the FDA to help ensure the safety and security of our nation’s pharmaceutical supply. We believe that direct distribution of medicine is the best near-term step to further secure the supply chain, which is one of the reasons Cardinal Health initiated this approach for all pharmaceuticals in 2005. In addition, we announced our support for enactment of the PDMA pedigree regulations in February, 2006 and recently launched the industry’s first end-to-end pilot program to test the use of radio frequency identification (RFID) under real-world conditions.
The safety and security of our nation’s pharmaceutical supply is Cardinal Health’s top priority and a responsibility we take very seriously. A safe and reliable drug supply is central to our customers’ business and critical to the health and well being of patients.
About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $75 billion, global company serving the health-care industry with a broad portfolio of products and services. Through its diverse offering, Cardinal Health delivers integrated health-care solutions that help customers reduce their costs, improve efficiency and deliver better care to patients. The company manufactures, packages and distributes pharmaceuticals and medical supplies, offers a range of clinical services and develops automation products that improve the management and delivery of supplies and medication for hospitals, physician offices and pharmacies. Ranked No. 19 on the Fortune 500, Cardinal Health employs more than 55,000 people on six continents. More information about the company may be found at www.cardinalhealth.com